Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Blood Adv. 2024 Jun 11;8(11):2880-2889. doi: 10.1182/bloodadvances.2023011388.
Inhibitor development is the most severe complication of hemophilia A (HA) care and is associated with increased morbidity and mortality. This study aimed to use a novel immunoglobulin G epitope mapping method to explore the factor VIII (FVIII)-specific epitope profile in the SIPPET cohort population and to develop an epitope mapping-based inhibitor prediction model. The population consisted of 122 previously untreated patients with severe HA who were followed up for 50 days of exposure to FVIII or 3 years, whichever occurred first. Sampling was performed before FVIII treatment and at the end of the follow-up. The outcome was inhibitor development. The FVIII epitope repertoire was assessed by means of a novel random peptide phage-display assay. A least absolute shrinkage and selection operator (LASSO) regression model and a random forest model were fitted on posttreatment sample data and validated in pretreatment sample data. The predictive performance of these models was assessed by the C-statistic and a calibration plot. We identified 27 775 peptides putatively directed against FVIII, which were used as input for the statistical models. The C-statistic of the LASSO and random forest models were good at 0.78 (95% confidence interval [CI], 0.69-0.86) and 0.80 (95% CI, 0.72-0.89). Model calibration of both models was moderately good. Two statistical models, developed on data from a novel random peptide phage display assay, were used to predict inhibitor development before exposure to exogenous FVIII. These models can be used to set up diagnostic tests that predict the risk of inhibitor development before starting treatment with FVIII.
抑制剂的产生是血友病 A(HA)治疗中最严重的并发症,与发病率和死亡率的增加有关。本研究旨在使用新型免疫球蛋白 G 表位作图方法探索 SIPPET 队列人群中因子 VIII(FVIII)的特异性表位谱,并开发一种基于表位作图的抑制剂预测模型。该人群包括 122 名先前未经治疗的重度 HA 患者,他们接受 FVIII 治疗 50 天或 3 年(以先发生者为准)的随访。在 FVIII 治疗前和随访结束时进行采样。结果是抑制剂的产生。通过新型随机肽噬菌体展示测定法评估 FVIII 表位库。在治疗后样本数据上拟合最小绝对收缩和选择算子(LASSO)回归模型和随机森林模型,并在预处理样本数据上进行验证。通过 C 统计量和校准图评估这些模型的预测性能。我们鉴定了 27775 个推测针对 FVIII 的肽,将其作为统计模型的输入。LASSO 和随机森林模型的 C 统计量在 0.78(95%置信区间 [CI],0.69-0.86)和 0.80(95%CI,0.72-0.89)上表现良好。两个模型的校准均为中等。两个基于新型随机肽噬菌体展示测定法数据开发的统计模型用于预测暴露于外源性 FVIII 之前抑制剂的产生。这些模型可用于建立诊断测试,以在开始 FVIII 治疗之前预测抑制剂产生的风险。